Positive Data from Cynata MSCs in Second Preclinical Asthma Study
Positive Data from Cynata MSCs in Second Preclinical Asthma Study • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma • Cymerus MSCs caused significantly greater reduction of airway…
Regenerative Medicine Industry Interface – a new industry collaboration in Victoria
Announcing RMI2 The Regenerative Medicine Industry Interface Regenerative Medicine An emerging field of medical science, regenerative medicine incorporates the use of cells, factors, and other biological building blocks, along with bioengineered materials and technologies for widespread clinical applications.…
Victorian medical emergency company Medical Developments International emerges as global leader
A Victorian emergency medicine company has risen to become a global leader, thanks to its range of respiratory medications. Offering new devices for asthma and chronic obstructive pulmonary disease (COPD), Medical Developments International (MDI), is turning its attention…
New collaboration for Alzheimer’s Research – SVI & Janssen
SVI has entered into a collaboration and license agreement with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceuticals Companies of Johnson & Johnson. The partnership is aimed at developing and commercialising small molecule modulators of microglial function…
An Australian first: Monash launches new Diabetes Department
Monash University today officially launched its new Department of Diabetes – the first and only university department in Australia dedicated to the disease. Opened by the Honourable Greg Hunt MP, Minister for Health, the new Department is a…
LBT Innovations Receives 2017 SA Science Excellence Award for Collaboration
LBT Innovations Ltd (LBT) has been awarded the 2017 SA Science Excellence Award for “Excellence in Research Collaboration”. The award recognises excellence in developing a world leading intelligent medical device in South Australia, and the collaboration between the…
VivaGel® BV demonstrated statistically significant efficacy in two pivotal phase 3 trials
VivaGel® BV consistently resulted in reduced rates of BV recurrence by the primary efficacy endpoint and five secondary efficacy measures, and delayed time to first recurrence VivaGel® BV resulted in sustained benefits 3 months after cessation of treatment…
LBT’S Woundvue™ Prototype to be Used at Central Adelaide Health Network
Australian medical technology company LBT Innovations Limited (ASX:LBT) has entered a collaboration agreement with Central Adelaide Local Health Network (CALHN) Vascular and Endovascular Services, to use LBT’s novel WoundVue™ prototype device in the clinical trial, “Predicting outcomes in…
State of the Sector Medical Technologies and Pharmaceuticals 2017
Victoria has one of the world’s largest life science clusters composed of the medical technology (medtech), biotechnology (biotech) and pharmaceutical industries. It is home to a vibrant commercial sector, key R&D infrastructure and advanced manufacturing expertise making it…
Clinical Trials in Australia: the economic profile and competitive position of the sector
Clinical trials are an integral part of the research and development of new treatments, interventions or tests, and the refinement of existing standards of care and clinical practices. As such, they are vital to the future of healthcare.…
Bionic vision a step closer with the CSIRO’s new computing system
People with profound vision loss are one step closer to having their sight effectively restored, thanks to a new investment from Australia’s chief science body into a large-scale scientific computing system. The new Bracewell system, which is being used by Data61’s computer vision group that…
LBT TO DISTRIBUTE APAS® IN AUSTRALIA & NZ
Australian medical technology company LBT Innovations Limited (ASX: LBT) has been appointed by joint venture company Clever Culture Systems AG (CCS) as the distributor for APAS® Independence in Australia and New Zealand. This will see LBT as the…
